What is Bicara Therapeutics's price / book?

Bicara Therapeutics (BCAX) reported price / book of 2.5× in Q1 2026.

How has Bicara Therapeutics's price / book changed year-over-year?

Bicara Therapeutics's price / book increased by 62.0% year-over-year, from 1.5× to 2.5×.

What does price / book mean?

Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Bicara Therapeutics BCAX Price / book

Price / book at other companies

Eli LillyLLY

26.3×-20.7×

AmgenAMGN

20.6×-6.3×

ArriVent BioPharma, Inc.AVBP

3.1×0.0×

ImmunomeIMNM

4.2×+2.3×

Arcus BiosciencesRCUS

5.2×+3.6×

Syndax PharmaceuticalsSNDX

49.5×+44.6×

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.64B+81.4%

Enterprise value$1.32B+288%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Calculated from Bicara Therapeutics’s reported figures.

market cap/total stockholders equity=2.5×

Based on the most recent quarter.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bicara Therapeutics's price / book?: Bicara Therapeutics (BCAX) reported price / book of 2.5× in Q1 2026.
How has Bicara Therapeutics's price / book changed year-over-year?: Bicara Therapeutics's price / book increased by 62.0% year-over-year, from 1.5× to 2.5×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.